JP2018535224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535224A5 JP2018535224A5 JP2018526543A JP2018526543A JP2018535224A5 JP 2018535224 A5 JP2018535224 A5 JP 2018535224A5 JP 2018526543 A JP2018526543 A JP 2018526543A JP 2018526543 A JP2018526543 A JP 2018526543A JP 2018535224 A5 JP2018535224 A5 JP 2018535224A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nanoparticle
- composition according
- patient
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257569P | 2015-11-19 | 2015-11-19 | |
| US62/257,569 | 2015-11-19 | ||
| PCT/US2016/062816 WO2017087825A1 (en) | 2015-11-19 | 2016-11-18 | Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018535224A JP2018535224A (ja) | 2018-11-29 |
| JP2018535224A5 true JP2018535224A5 (enExample) | 2019-12-26 |
Family
ID=58717907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526543A Pending JP2018535224A (ja) | 2015-11-19 | 2016-11-18 | 抗血管新生、抗リンパ管新生及び抗浮腫特性を有するペプチド及びナノ粒子製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180339024A1 (enExample) |
| EP (1) | EP3377080B1 (enExample) |
| JP (1) | JP2018535224A (enExample) |
| KR (1) | KR20180081608A (enExample) |
| CN (1) | CN108883150A (enExample) |
| AU (1) | AU2016358125A1 (enExample) |
| BR (1) | BR112018010052A2 (enExample) |
| CA (1) | CA3005284A1 (enExample) |
| IL (1) | IL259376A (enExample) |
| MX (1) | MX2018006194A (enExample) |
| SG (2) | SG10202004259PA (enExample) |
| WO (1) | WO2017087825A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ771201A (en) | 2017-04-06 | 2025-01-31 | Sustain Holdings Llc | Collagen Peptide-Based Medicament Compositions And Devices And Methods Of Production And Use Thereof |
| US11674959B2 (en) | 2017-08-03 | 2023-06-13 | The Johns Hopkins University | Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors |
| US20210113654A1 (en) * | 2018-05-31 | 2021-04-22 | Yale University | Methods and Compositions to Alleviate Vascular Permeability |
| CA3134816A1 (en) * | 2019-03-26 | 2020-10-01 | Asclepix Therapeutics, Inc. | Compositions and methods for treating ocular disease |
| SG11202112487QA (en) | 2019-04-22 | 2021-12-30 | Sustain Holdings Llc | Collagen peptide-based medicament compositions and devices and methods of production and use thereof |
| WO2021178949A1 (en) * | 2020-03-06 | 2021-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody fragments conjugated to peg-plga nanoparticles improve immunotherapy against cancer cells |
| GB202004514D0 (en) | 2020-03-27 | 2020-05-13 | Inst De Medicina Molecular Joaeo Lobo Antunes | Treatment of Immunosuppressive Cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| ES2210306T3 (es) | 1994-07-20 | 2004-07-01 | The General Hospital Corporation | Sistemas de trampa para interacciones, para detectar interacciones de proteinas. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| ES2402878T3 (es) | 1999-05-05 | 2013-05-10 | Phylogica Limited | Aislamiento de moduladores biológicos a partir de colecciones de fragmentos génicos biodiversos |
| DE60045243D1 (de) | 1999-05-26 | 2010-12-30 | Next Biomed Technologies Nbt Oy | VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| EP2284270A3 (en) | 2000-12-13 | 2012-07-25 | Anaphore, Inc. | Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains |
| CN1628126A (zh) | 2001-08-30 | 2005-06-15 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| WO2004031733A2 (en) | 2002-10-02 | 2004-04-15 | Catalyst Biosciences | Methods of generating and screenign for porteases with altered specificity |
| PT1587907E (pt) | 2003-01-07 | 2011-04-08 | Dyax Corp | Biblioteca de domínios de kunitz |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| WO2008085828A2 (en) * | 2007-01-03 | 2008-07-17 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
| SI2185589T1 (sl) | 2007-06-01 | 2016-04-29 | University Of Maryland Baltimore | Vezavna sredstva za Fc receptor konstantne regije imunoglobulina |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| US8992991B2 (en) * | 2009-05-15 | 2015-03-31 | The Johns Hopkins University | Multicomponent degradable cationic polymers |
| WO2011084509A1 (en) * | 2009-12-15 | 2011-07-14 | Massachusetts Institute Of Technology | Endothelial basement membrane targeting peptide ligands |
| WO2012079088A2 (en) * | 2010-12-10 | 2012-06-14 | The Johns Hopkins University | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| US9309286B2 (en) * | 2011-08-17 | 2016-04-12 | Tufts Medical Center | Compositions and methods for augmenting permeability barriers |
| US10758487B2 (en) | 2011-12-09 | 2020-09-01 | The Johns Hopkins University | Artificial antigen presenting cells having a defined and dynamic shape |
| WO2014018018A1 (en) * | 2012-07-24 | 2014-01-30 | Morehouse School Of Medicine | Composition and method for reducing tissue damage from inflammatory disorder or pathogenic infection |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| JP6470740B2 (ja) * | 2013-06-07 | 2019-02-13 | ザ ジョンズ ホプキンス ユニバーシティ | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
| SG11201602522VA (en) * | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
-
2016
- 2016-11-18 EP EP16867239.2A patent/EP3377080B1/en active Active
- 2016-11-18 SG SG10202004259PA patent/SG10202004259PA/en unknown
- 2016-11-18 BR BR112018010052A patent/BR112018010052A2/pt not_active IP Right Cessation
- 2016-11-18 US US15/776,971 patent/US20180339024A1/en not_active Abandoned
- 2016-11-18 WO PCT/US2016/062816 patent/WO2017087825A1/en not_active Ceased
- 2016-11-18 AU AU2016358125A patent/AU2016358125A1/en not_active Abandoned
- 2016-11-18 KR KR1020187017365A patent/KR20180081608A/ko not_active Withdrawn
- 2016-11-18 CA CA3005284A patent/CA3005284A1/en not_active Abandoned
- 2016-11-18 SG SG11201804003VA patent/SG11201804003VA/en unknown
- 2016-11-18 JP JP2018526543A patent/JP2018535224A/ja active Pending
- 2016-11-18 MX MX2018006194A patent/MX2018006194A/es unknown
- 2016-11-18 CN CN201680078709.0A patent/CN108883150A/zh active Pending
-
2018
- 2018-05-15 IL IL259376A patent/IL259376A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yasmin et al. | Novel drug delivery systems for inflammatory bowel disease | |
| Du et al. | Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation | |
| Wu et al. | Innovative nanotechnology in drug delivery systems for advanced treatment of posterior segment ocular diseases | |
| Khan et al. | PLGA nanoparticles and their versatile role in anticancer drug delivery | |
| CN109890420B (zh) | 用于递送治疗剂的血小板组合物和方法 | |
| Cabeza et al. | Nanoparticles in colorectal cancer therapy: latest in vivo assays, clinical trials, and patents | |
| Hu et al. | Tumor microenvironment-mediated construction and deconstruction of extracellular drug-delivery depots | |
| Liu et al. | Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables treatment of eye diseases using significantly reduced dosage | |
| JP6343147B2 (ja) | 狭窄病変および血栓溶解療法のための剪断による制御放出 | |
| Pinto et al. | Targeted brain delivery nanoparticles for malignant gliomas | |
| US20170333365A1 (en) | Core-shell particle formulation for delivering multiple therapeutic agents | |
| JP2016521712A5 (enExample) | ||
| CN102970864A (zh) | 纳米颗粒药物组合物 | |
| Guo et al. | Transferrin-functionalized microemulsions coloaded with coix seed oil and tripterine deeply penetrate to improve cervical cancer therapy | |
| Morales-Orue et al. | Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies | |
| Zhao et al. | Teaching new tricks to old dogs: A review of drug repositioning of disulfiram for cancer nanomedicine | |
| CA3005284A1 (en) | Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations | |
| Jeswani et al. | Advances in the delivery of cancer therapeutics: a comprehensive review | |
| Joshi et al. | Inhibition of cancer cell metastasis by nanotherapeutics: current achievements and future trends | |
| Su et al. | Eudragit S100 coated nanodiamond-based nanoparticles as an oral chemo-photothermal delivery system for local treatment of colon cancer | |
| Al-Amili et al. | Self-assembled micelles of amphiphilic PEGylated drugs for cancer treatment | |
| Yang et al. | Intravenous administration of scutellarin nanoparticles augments the protective effect against cerebral ischemia–reperfusion injury in rats | |
| Mishra et al. | Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles | |
| Wei et al. | Cell-and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy | |
| Panchangam et al. | Engineered nanoparticles for the delivery of anticancer therapeutics |